Skip to main content

and
Your search also matched 31 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer

Include preview-only content
  1. Article

    Open Access

    A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

    Breast-conserving surgery with radiotherapy is one of standard treatments for early breast cancer. However, it is regarded as an option to treat elderly patients with small hormone receptor-positive breast can...

    Shozo Ohsumi, Reiki Nishimura, Norikazu Masuda, Sadako Akashi-Tanaka in Breast Cancer (2023)

  2. Article

    Open Access

    Correction to: Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

    Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, Shinji Ohno in Breast Cancer (2022)

  3. Article

    Open Access

    Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial

    This retrospective observational study validated nuclear grading criteria developed to identify a high-risk group with recurrence rate ≥20–30% and local pathology diagnosis used in a previous multi-institution...

    Hitoshi Tsuda, Masafumi Kurosumi, Futoshi Akiyama, Shinji Ohno in Breast Cancer (2022)

  4. Article

    Open Access

    Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

    The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR+) breast cancer refractory to letrozo...

    Shinzaburo Noguchi, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai in Breast Cancer (2014)

  5. Article

    Management of breast cancer: from standardization to personalization

    Hideo Inaji in Breast Cancer (2009)